港股異動 | 神威藥業升4% 中藥1.1類創新藥異功散顆粒獲批臨牀
格隆匯4月6日丨神威藥業(2877.HK)升4%,報8.28港元,總市值68億港元。神威藥業集團收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》,准予神威藥業集團自主研發的中藥1.1類創新藥——異功散顆粒開展臨牀試驗。異功散顆粒來源於宋代經典名方,臨牀應用已900餘年,用於治療慢性病貧血,中醫通常將慢性病貧血歸屬於“萎黃”“黃病”或“血虛證”等範疇,目前市場上無明確治療慢性病貧血的中成藥。研究顯示,異功散顆粒臨牀治療慢性病貧血療效確切,尤其針對EPO治療無效者,更凸顯其臨牀價值。異功散顆粒的開發及上市將填補慢性病貧血治療的市場空白,滿足臨牀需求,具有重大的臨牀價值及社會價值。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.